Werewolf Therapeutics’ Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting
Werewolf Therapeutics, Inc. (HOWL) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Werewolf Therapeutics’ Clinical Data for WTX-124 and WTX-330 Presented at the Society for Immunotherapy of Cancer’s (SITC) 2026 Annual Meeting – In a Phase 1/1b clinical trial , WTX-124 was administered safely at its recommended Phase 2 dose of 18 mg IV Q2W in the ou
- Product
- WTX-124
- Milestone
- topline data
- Indication
- relapsed/refractory immunotherapy-sensitive solid tumors
Facts are quoted from the filing text and checked against it.
How this was made
The 30-second read
Why it matters
The disclosed data suggest safety and efficacy, potentially de‑risking the programs and supporting future financing or partnership opportunities.
Market read
First‑time disclosure of early clinical data for a micro‑cap biotech; could trigger short‑term price movement and longer‑term valuation shifts.
What to watch
Small patient cohorts and lack of long‑term survival data could limit the impact.
Background
Werewolf Therapeutics (NASDAQ: HOWL) announced Phase 1/1b results for WTX-124 and Phase 1b/2 results for WTX-330 at the Society for Immunotherapy of Cancer's 2026 annual meeting.
Ticker impact
Werewolf Therapeutics disclosed new Phase 1/1b data for WTX-124 and Phase 1b/2 data for WTX-330 at the SITC 2026 meeting.
upward pressure as investors price in promising early‑stage data.
The data show durable responses and manageable safety, which are material for a micro‑cap biotech and may trigger buying interest.
Market effects
Early‑stage IL‑2/IL‑12 IND‑UKINE data could boost sentiment in the immunotherapy and broader biotech sector.
US biotech market may see modest buying pressure.
Limited to investors tracking early‑stage oncology pipelines.
Counterpoint
Early data may not translate to later‑stage trials; investors should be cautious of over‑optimism.
Key entities
- companyWerewolf Therapeutics
Biopharma developing conditionally activated IL‑2 and IL‑12 therapeutics.
- drug_candidateWTX-124
Conditionally activated IL‑2 prodrug showing responses in solid tumors.
- drug_candidateWTX-330
Conditionally activated IL‑12 prodrug with early activity signals.


